Exagen Capex To Revenue vs Ebit Per Revenue Analysis

XGN Stock

USD 5.02 0.07 1.41%

Exagen financial indicator trend analysis is much more than just examining Exagen Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Exagen Inc is a good investment. Please check the relationship between Exagen Capex To Revenue and its Ebit Per Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Exagen Inc Capex To Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Exagen's Capex To Revenue and Ebit Per Revenue is -0.98. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Exagen Inc, assuming nothing else is changed. The correlation between historical values of Exagen's Capex To Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Exagen Inc are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Capex To Revenue i.e., Exagen's Capex To Revenue and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

-0.98

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Ebit Per Revenue

Most indicators from Exagen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Exagen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

At this time, Exagen's Tax Provision is very stable compared to the past year. As of the 26th of December 2024, Sales General And Administrative To Revenue is likely to grow to 1.51, while Selling General Administrative is likely to drop about 30.6 M.

	2021	2022	2023	2024 (projected)
Interest Expense	2.6M	2.4M	2.3M	2.8M
Depreciation And Amortization	948K	2.1M	2.2M	2.3M

Interest Expense Depreciation And Amortization

Exagen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.7	0.8	-0.1	0.95	0.54	-0.2	-0.94	-0.71	0.65	1.0	0.33	-0.38	1.0	-0.33	0.54	0.86	0.81	0.87	0.91	0.67	0.45	1.0	-0.34	0.83	0.7
Short Long Term Debt Total	0.7		0.81	0.38	0.44	0.58	0.34	-0.41	-0.79	0.88	0.67	0.49	0.15	0.67	-0.42	0.23	0.65	0.78	0.73	0.64	0.99	0.49	0.69	0.07	0.54	0.73
Other Current Liab	0.8	0.81		0.02	0.65	0.58	0.02	-0.62	-0.89	0.85	0.77	0.19	-0.26	0.77	-0.48	0.32	0.8	0.85	0.8	0.83	0.79	0.58	0.8	-0.31	0.72	0.87
Total Current Liabilities	-0.1	0.38	0.02		-0.32	0.04	0.6	0.32	0.0	0.37	-0.14	0.59	0.93	-0.14	-0.01	0.26	-0.07	-0.27	-0.08	-0.08	0.47	0.04	-0.13	0.93	-0.11	0.13
Total Stockholder Equity	0.95	0.44	0.65	-0.32		0.43	-0.42	-1.0	-0.55	0.43	0.96	0.17	-0.57	0.96	-0.23	0.56	0.79	0.69	0.78	0.86	0.39	0.34	0.95	-0.49	0.8	0.55
Property Plant And Equipment Net	0.54	0.58	0.58	0.04	0.43		-0.07	-0.37	-0.84	0.66	0.5	0.67	-0.04	0.5	-0.94	0.5	0.8	0.56	0.38	0.73	0.56	0.95	0.51	-0.17	0.71	0.82
Current Deferred Revenue	-0.2	0.34	0.02	0.6	-0.42	-0.07		0.4	-0.06	0.23	-0.22	0.23	0.58	-0.22	0.05	-0.32	-0.2	-0.03	-0.13	-0.29	0.41	-0.03	-0.22	0.54	-0.29	-0.01
Net Debt	-0.94	-0.41	-0.62	0.32	-1.0	-0.37	0.4		0.51	-0.39	-0.95	-0.15	0.56	-0.95	0.18	-0.55	-0.76	-0.65	-0.76	-0.82	-0.37	-0.29	-0.94	0.47	-0.78	-0.51
Retained Earnings	-0.71	-0.79	-0.89	0.0	-0.55	-0.84	-0.06	0.51		-0.84	-0.67	-0.38	0.18	-0.67	0.79	-0.34	-0.89	-0.81	-0.68	-0.81	-0.76	-0.86	-0.7	0.31	-0.8	-0.92
Accounts Payable	0.65	0.88	0.85	0.37	0.43	0.66	0.23	-0.39	-0.84		0.61	0.53	0.1	0.61	-0.55	0.41	0.72	0.68	0.7	0.74	0.88	0.62	0.63	0.06	0.63	0.85
Cash	1.0	0.67	0.77	-0.14	0.96	0.5	-0.22	-0.95	-0.67	0.61		0.28	-0.41	1.0	-0.28	0.52	0.83	0.79	0.86	0.89	0.62	0.4	1.0	-0.36	0.81	0.66
Non Current Assets Total	0.33	0.49	0.19	0.59	0.17	0.67	0.23	-0.15	-0.38	0.53	0.28		0.5	0.28	-0.51	0.56	0.4	0.13	0.1	0.4	0.55	0.54	0.28	0.48	0.33	0.5
Non Currrent Assets Other	-0.38	0.15	-0.26	0.93	-0.57	-0.04	0.58	0.56	0.18	0.1	-0.41	0.5		-0.41	-0.01	0.1	-0.29	-0.47	-0.36	-0.32	0.23	-0.03	-0.42	0.95	-0.32	-0.05
Cash And Short Term Investments	1.0	0.67	0.77	-0.14	0.96	0.5	-0.22	-0.95	-0.67	0.61	1.0	0.28	-0.41		-0.28	0.52	0.83	0.79	0.86	0.89	0.62	0.4	1.0	-0.36	0.81	0.66
Good Will	-0.33	-0.42	-0.48	-0.01	-0.23	-0.94	0.05	0.18	0.79	-0.55	-0.28	-0.51	-0.01	-0.28		-0.44	-0.73	-0.4	-0.26	-0.6	-0.41	-0.98	-0.31	0.17	-0.67	-0.76
Common Stock Total Equity	0.54	0.23	0.32	0.26	0.56	0.5	-0.32	-0.55	-0.34	0.41	0.52	0.56	0.1	0.52	-0.44		0.65	0.08	0.4	0.71	0.26	0.48	0.52	0.18	0.71	0.54
Common Stock Shares Outstanding	0.86	0.65	0.8	-0.07	0.79	0.8	-0.2	-0.76	-0.89	0.72	0.83	0.4	-0.29	0.83	-0.73	0.65		0.71	0.78	0.94	0.62	0.81	0.85	-0.33	0.98	0.85
Non Current Liabilities Total	0.81	0.78	0.85	-0.27	0.69	0.56	-0.03	-0.65	-0.81	0.68	0.79	0.13	-0.47	0.79	-0.4	0.08	0.71		0.81	0.73	0.72	0.47	0.81	-0.56	0.62	0.69
Other Current Assets	0.87	0.73	0.8	-0.08	0.78	0.38	-0.13	-0.76	-0.68	0.7	0.86	0.1	-0.36	0.86	-0.26	0.4	0.78	0.81		0.79	0.68	0.33	0.88	-0.34	0.79	0.58
Other Stockholder Equity	0.91	0.64	0.83	-0.08	0.86	0.73	-0.29	-0.82	-0.81	0.74	0.89	0.4	-0.32	0.89	-0.6	0.71	0.94	0.73	0.79		0.61	0.68	0.9	-0.33	0.92	0.87
Total Liab	0.67	0.99	0.79	0.47	0.39	0.56	0.41	-0.37	-0.76	0.88	0.62	0.55	0.23	0.62	-0.41	0.26	0.62	0.72	0.68	0.61		0.49	0.65	0.16	0.52	0.72
Property Plant And Equipment Gross	0.45	0.49	0.58	0.04	0.34	0.95	-0.03	-0.29	-0.86	0.62	0.4	0.54	-0.03	0.4	-0.98	0.48	0.81	0.47	0.33	0.68	0.49		0.42	-0.17	0.74	0.82
Total Current Assets	1.0	0.69	0.8	-0.13	0.95	0.51	-0.22	-0.94	-0.7	0.63	1.0	0.28	-0.42	1.0	-0.31	0.52	0.85	0.81	0.88	0.9	0.65	0.42		-0.38	0.83	0.68
Short Term Debt	-0.34	0.07	-0.31	0.93	-0.49	-0.17	0.54	0.47	0.31	0.06	-0.36	0.48	0.95	-0.36	0.17	0.18	-0.33	-0.56	-0.34	-0.33	0.16	-0.17	-0.38		-0.33	-0.17
Intangible Assets	0.83	0.54	0.72	-0.11	0.8	0.71	-0.29	-0.78	-0.8	0.63	0.81	0.33	-0.32	0.81	-0.67	0.71	0.98	0.62	0.79	0.92	0.52	0.74	0.83	-0.33		0.76
Common Stock	0.7	0.73	0.87	0.13	0.55	0.82	-0.01	-0.51	-0.92	0.85	0.66	0.5	-0.05	0.66	-0.76	0.54	0.85	0.69	0.58	0.87	0.72	0.82	0.68	-0.17	0.76

Click cells to compare fundamentals

Exagen Account Relationship Matchups

Exagen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	88.3M	78.4M	123.4M	86.2M	56.9M	54.2M
Short Long Term Debt Total	26.1M	26.7M	27.5M	34.5M	23.7M	23.8M
Other Current Liab	4.2M	5.4M	6.2M	4.6M	7.0M	3.9M
Total Current Liabilities	5.9M	8.8M	9.3M	9.6M	11.9M	9.7M
Total Stockholder Equity	55.7M	41.8M	84.9M	42.5M	22.7M	20.5M
Property Plant And Equipment Net	1.4M	2.1M	4.8M	13.1M	8.5M	8.9M
Net Debt	(46.2M)	(30.8M)	(72.0M)	(27.9M)	(12.8M)	(13.4M)
Retained Earnings	(164.6M)	(181.3M)	(208.1M)	(255.5M)	(279.2M)	(265.3M)
Accounts Payable	1.5M	3.0M	2.5M	3.0M	3.1M	2.1M
Cash	72.1M	57.4M	99.4M	62.4M	36.5M	37.0M
Non Current Assets Total	7.1M	7.9M	10.7M	13.6M	9.1M	10.2M
Non Currrent Assets Other	174K	(487K)	(391K)	528K	616K	542.5K
Cash And Short Term Investments	72.1M	57.4M	99.4M	62.4M	36.5M	37.0M
Common Stock Shares Outstanding	12.6M	12.7M	16.0M	17.1M	17.7M	18.6M
Liabilities And Stockholders Equity	88.3M	78.4M	123.4M	86.2M	56.9M	54.2M
Non Current Liabilities Total	26.8M	27.8M	29.2M	34.1M	22.3M	20.3M
Other Current Assets	3.5M	4.2M	2.5M	2.3M	1.9M	1.8M
Other Stockholder Equity	220.2M	223.1M	293.1M	298.0M	301.9M	164.6M
Total Liab	32.7M	36.5M	38.5M	43.8M	34.3M	33.7M
Property Plant And Equipment Gross	1.4M	2.1M	4.8M	13.1M	14.3M	15.0M
Total Current Assets	81.3M	70.5M	112.7M	72.6M	47.8M	44.0M
Short Term Debt	238K	308K	587K	1.9M	1.7M	1.6M
Other Assets	174K	250K	433K	528K	475.2K	894.3K
Net Receivables	5.7M	8.9M	9.7M	6.1M	6.6M	6.0M
Property Plant Equipment	1.4M	2.1M	4.8M	13.1M	15.0M	15.8M
Other Liab	266K	530K	1.7M	19K	17.1K	16.2K
Net Tangible Assets	50.2M	36.3M	79.4M	42.5M	48.8M	51.3M
Long Term Debt	25.9M	26.7M	27.5M	28.8M	19.2M	21.0M
Capital Lease Obligations	238K	308K	587K	6.2M	4.2M	4.4M
Inventory	1.4M	1.2M	1.1M	1.8M	2.9M	3.0M
Non Current Liabilities Other	638K	948K	1.4M	867K	357K	567.1K

Pair Trading with Exagen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Exagen Stock

0.79

DMAC

DiaMedica Therapeutics

Pair Corr

Moving against Exagen Stock

0.93	VIGL	Vigil Neuroscience	Pair Corr
0.91	DTIL	Precision BioSciences	Pair Corr
0.86	VALN	Valneva SE ADR	Pair Corr
0.86	DRRX	Durect	Pair Corr
0.77	DNLI	Denali Therapeutics	Pair Corr

The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.

The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:

How To Invest In Exagen

Details

Is Exagen Stock a good investment?

Details

What is Exagen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.94)

Revenue Per Share

3.163

Quarterly Revenue Growth

0.066

Return On Assets

(0.17)

Return On Equity

(0.70)

The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Exagen Capex To Revenue vs Ebit Per Revenue Analysis

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Ebit Per Revenue

Exagen fundamental ratios Correlations

Exagen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Exagen fundamental ratios Accounts

Pair Trading with Exagen

Moving together with Exagen Stock

Moving against Exagen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Net Debt	- 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	- 0.98	Good Will
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Total Current Assets	- 0.94	Net Debt
Good Will	- 0.94	Property Plant And Equipment Net